CA3242136A1 - Clinical formulations of anti-tigit antibodies - Google Patents

Clinical formulations of anti-tigit antibodies

Info

Publication number
CA3242136A1
CA3242136A1 CA3242136A CA3242136A CA3242136A1 CA 3242136 A1 CA3242136 A1 CA 3242136A1 CA 3242136 A CA3242136 A CA 3242136A CA 3242136 A CA3242136 A CA 3242136A CA 3242136 A1 CA3242136 A1 CA 3242136A1
Authority
CA
Canada
Prior art keywords
manufacture
monoclonal antibodies
pharmaceutical formulations
tigit
tigit antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242136A
Other languages
English (en)
French (fr)
Inventor
Ian Chung-ti SHIEH
Ann Marie WOYS
Katherine Laura TSCHUDI
Robyn Mariah SUHLING
Rucha Sudhakar SANE
Hui Min Phyllis CHAN
Xiaohui Wen
Isabelle Anne ROONEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA3242136A1 publication Critical patent/CA3242136A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3242136A 2021-12-22 2022-12-21 Clinical formulations of anti-tigit antibodies Pending CA3242136A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163292863P 2021-12-22 2021-12-22
US63/292,863 2021-12-22
US202263383451P 2022-11-11 2022-11-11
US63/383,451 2022-11-11
US202263387229P 2022-12-13 2022-12-13
US63/387,229 2022-12-13
PCT/US2022/082139 WO2023122665A1 (en) 2021-12-22 2022-12-21 Clinical formulations of anti-tigit antibodies

Publications (1)

Publication Number Publication Date
CA3242136A1 true CA3242136A1 (en) 2023-06-29

Family

ID=85199491

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242136A Pending CA3242136A1 (en) 2021-12-22 2022-12-21 Clinical formulations of anti-tigit antibodies

Country Status (10)

Country Link
US (1) US20240408009A1 (cg-RX-API-DMAC7.html)
EP (1) EP4452320A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500483A (cg-RX-API-DMAC7.html)
KR (1) KR20240121771A (cg-RX-API-DMAC7.html)
AU (1) AU2022417501A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242136A1 (cg-RX-API-DMAC7.html)
IL (1) IL313658A (cg-RX-API-DMAC7.html)
MX (1) MX2024007749A (cg-RX-API-DMAC7.html)
TW (1) TW202330034A (cg-RX-API-DMAC7.html)
WO (1) WO2023122665A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515614A (zh) 2023-08-25 2025-04-16 美商建南德克公司 治療非小細胞肺癌之方法及組成物
WO2025174933A1 (en) 2024-02-14 2025-08-21 Genentech, Inc. Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP2023504748A (ja) 2019-12-09 2023-02-06 ジェネンテック, インコーポレイテッド 抗pd-l1抗体製剤
CN115052622B (zh) * 2020-01-21 2026-03-06 夏尔巴生物技术(杭州)有限公司 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途
IL294800A (en) * 2020-01-27 2022-09-01 Genentech Inc Methods of treating cancer with an antibody to an anti-ti antagonist

Also Published As

Publication number Publication date
KR20240121771A (ko) 2024-08-09
WO2023122665A1 (en) 2023-06-29
EP4452320A1 (en) 2024-10-30
MX2024007749A (es) 2024-07-01
AU2022417501A1 (en) 2024-07-04
IL313658A (en) 2024-08-01
US20240408009A1 (en) 2024-12-12
TW202330034A (zh) 2023-08-01
JP2025500483A (ja) 2025-01-09

Similar Documents

Publication Publication Date Title
US11707448B2 (en) Combination therapies for the treatment of cancer
RU2430739C2 (ru) Способ лечения рака у человека (варианты), применяемая в способе форма (варианты) и применение антитела (варианты)
JP2019517549A5 (cg-RX-API-DMAC7.html)
JP7491220B2 (ja) 免疫チェックポイント阻害薬およびfolfirinox療法との併用によるがん治療
RU2009110102A (ru) Лечение опухолей с помощью антитела к vegf
RU2019112029A (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
RU2008141433A (ru) Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста
MX2024007749A (es) Formulaciones clinicas de anticuerpos anti-tigit.
JP2022513029A5 (cg-RX-API-DMAC7.html)
NZ740351A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
FI3888647T3 (fi) Ezh1/2-kaksoisestäjän sisältävä farmaseuttinen koostumus käytettäväksi yhdistelmälääkkeenä
WO2020081579A8 (en) Monoclonal antibodies against human dickkopf3 and uses thereof
IL308020A (en) Combination of anti-galectin-9 antibodies and chemotherapeutic agents for use in cancer treatment
CN113573702A (zh) 用于癌症治疗的亚达司他的组合
WO2024206868A3 (en) Methods of treating tumors with anti-tigit antibodies
WO2023164581A3 (en) Fully human monoclonal antibodies against human progranulin
CN112955148A (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
MX2022015232A (es) Composicion farmaceutica acuosa de levilimab y su uso.
EA201791075A1 (ru) Способы лечения опухолей с применением биспецифического антитела cd3×cd20
EP3127545B1 (en) Anti-tumor drug containing taxane compound, and anti-tumor effect enhancer
MX2025001881A (es) Terapia que comprende anticuerpos anti cumulo de diferenciacion 19 (cd19) y moduladores del homologo 2 del potenciador de la proteina zeste (ezh2)
WO2023001283A9 (zh) 用于治疗胃癌和/或食管胃结合部癌的联用药物
WO2023164277A3 (en) Anti-programmed death-ligand 1 (pd-l1) antibodies
MX2025010617A (es) Metodos para tratar la colitis ulcerosa
US20050163707A1 (en) Cancer treatment

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20240910

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251121